Clinical Trials Browser

Phase 1/2 × Neuroendocrine Tumors × lanreotide × Clear all

NCT05048901 2024-07-05

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors